A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

NCT02906605 · clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class

Stopped Study start delayed due to pending collection and analysis of additional phase 1 data.

Conditions

Interventions

Sponsor

Janssen Research & Development, LLC